Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vectura Group has released positive results from a Phase II study evaluating VR496, an inhaled product to treat respiratory symptoms linked with airway disorder such as cystic fibrosis (CF).
Subscribe to our email newsletter
The results suggested that VR496 was safe and well tolerated in which 90% of the patients have successfully completed the trial.
The trial showed anti -inflammatory activity via reductions, from Baseline to Week 4, in induced sputum neutrophil elastase and total cell counts when compared to placebo.
Cardiff University Department of Medicine Dennis Shale said this study was the first opportunity to evaluate inhaled dry powder heparin sodium in CF patients.
"The resultant data illustrated excellent systemic and local safety and evidence of anti-inflammatory and mucolytic activity," Shale said.
"This multi-modal profile differentiates VR496 from current treatment options and confirms its potential to address unmet treatment requirements in CF and other inflammatory airway disorders."